Molecular Partners

Molecular Partners Liabilities

The The Liabilities of Molecular Partners (MOLN.SW) as of Nov 13, 2026 is 21.77 M CHF. In the previous year, The Liabilities was 16.89 M CHF — a change of 28.90% (higher).

Liabilities

21.77 MCHF

YoY

28.90%

Last updated:

In 2025, Molecular Partners's total liabilities amounted to 21.77 M CHF, a 28.90% difference from the 16.89 M CHF total liabilities in the previous year.

The Molecular Partners Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
63.45 M CHF
Jan 1, 2019
50.80 M CHF
Jan 1, 2020
80.33 M CHF
Jan 1, 2021
65.38 M CHF
Jan 1, 2022
27.09 M CHF
Jan 1, 2023
21.92 M CHF
Jan 1, 2024
16.89 M CHF
Jan 1, 2025
21.77 M CHF
The Molecular Partners Liabilities history
YEARLiabilitiesYoY
21.77 MCHF+28.90%
16.89 MCHF-22.95%
21.92 MCHF-19.08%
27.09 MCHF-58.56%
65.38 MCHF-18.61%
80.33 MCHF+58.13%
50.80 MCHF-19.95%
63.45 MCHF+129.12%
27.69 MCHF-42.67%
48.30 MCHF-28.55%
67.60 MCHF+48.44%
45.54 MCHF—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Molecular Partners Stock analysis

What does Molecular Partners do? Molecular Partners AG is a biopharmaceutical company based in Zurich, specializing in the research and development of novel therapies in the fields of cancer and ophthalmology. The company was founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETHZ) and has since made significant progress in drug research and development. The business model of Molecular Partners is based on the development of so-called DARPins (Designed Ankyrin Repeat Proteins). DARPins are artificially created protein molecules that can be used as highly specific binding partners in drug research and development. Due to their modular structure and flexibility, DARPins can bind to a variety of target molecules, thus serving as a basis for the development of new therapies. The various divisions of Molecular Partners focus on the development of therapies in the areas of cancer and ophthalmology. In the field of cancer, the company has a number of promising drug candidates based on DARPins in preclinical and clinical development. One of the most promising candidates is MP0250, a bispecific DARPin that targets two targets and is intended to suppress cancer cell activity. In the field of ophthalmology, Molecular Partners is developing therapies for the treatment of retinal diseases and other eye diseases. One of the most promising candidates in this area is Abicipar, an anti-VEGF DARPin that can be used to treat wet age-related macular degeneration and other retinal diseases. Abicipar has already shown promising results in clinical trials and is currently being submitted for approval to US and European regulatory authorities. Molecular Partners has formed partnerships with leading pharmaceutical and biotech companies such as Amgen, Allergan, Novartis, and Nestlé Health Science to support the development and commercialization of their drug candidates. In addition, the company has entered into a number of licensing and collaboration agreements with other companies to advance the development of new therapies. Overall, Molecular Partners has made significant progress in the development of novel therapies in the fields of cancer and ophthalmology in recent years. The company has developed a unique platform technology on which a variety of therapies can be based, tailored to the specific needs of patients. With its strong partnerships and pipeline of drug candidates, Molecular Partners is well positioned to continue growing and developing new treatment options for patients in the coming years. Molecular Partners is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Molecular Partners's Liabilities

Molecular Partners's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Molecular Partners's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Molecular Partners's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Molecular Partners's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Molecular Partners’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Molecular Partners stock

The Liabilities of Molecular Partners is 21.77 M CHF in 2025.

The Liabilities of Molecular Partners changed from 16.89 M CHF to 21.77 M CHF, representing a 28.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Molecular Partners since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CHF is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Molecular Partners historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Molecular Partners

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Molecular Partners